UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report
(Date of earliest event reported): August 9, 2010
 
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware
001-15281
76-0233274
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
2408 Timberloch Place, Suite B-7
The Woodlands, Texas  77380
(Address of principal
executive offices
and zip code)
 
(281) 719-3400
(Registrant’s telephone number, including area code)
  


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[  ]           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 2.02  Results of Operations and Financial Condition.
 
The information in this Item of this Current Report is being furnished pursuant to Item 2.02 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Item of this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item of this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.
 
On August 9, 2010, Repros Therapeutics Inc. (the “Company”) announced financial results for the second quarter ended June 30, 2010.  Additional information is included in the Company’s press release dated August 9, 2010.
 
A copy of the Company’s press release is attached hereto as Exhibit 99.1.  The foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.
 
Item 8.01  Other Events.
 
On August 9, 2010, the Company issued a press release titled “Repros Receives Positive Feedback from the Division of Reproductive and Urologic Products for Androxal® in the Treatment of Hypogonadal Men Wishing to Preserve Fertility.”  A copy of such press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01  Financial Statements and Exhibits.
 
(d)  Exhibits.
 
Exhibit
  
Number
Description
   99.1
Earnings Release dated August 9, 2010
   
   99.2
Press Release dated August 9, 2010
 
 
 
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Repros Therapeutics Inc.
     
Date: August 9, 2010
    
     
By:
/s/ Joseph S. Podolski                          
   
Joseph S. Podolski
   
President and Chief Executive Officer

 
 
 
 
 
EXHIBIT INDEX
 
Exhibit
  
Number
Description
   99.1
Earnings Release dated August 9, 2010
   
   99.2
Press Release dated August 9, 2010